SGLT2 inhibition for outcomes: Is this the panacea?
The use of SGLT2 inhibitors, beyond present guideline-directed medical therapy for patients with type 2 diabetes, chronic kidney disease, high atherosclerotic cardiovascular risk and heart failure, may in the future become a significant addition to the treatment of patients with acute myocardial inf...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | American Heart Journal Plus |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666602222000763 |